Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24922956 | 1.00 | HSD17B10 (0.44) | HSD17B10ALDH1A1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL18015115 | 0.87 | ALOX5AP (0.45) | HSD17B10ALDH1A1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL18015118 | 0.87 | ALOX5AP (0.45) | HSD17B10ALDH1A1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL18015133 | 0.87 | ALOX5AP (0.45) | HSD17B10ALDH1A1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL21520598 | 0.85 | HSD17B10 (0.43) | HSD17B10ALDH1A1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL19768833 | 0.85 | PDE8B (0.42) | HSD17B10ALDH1A1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL24760647 | 0.85 | HPGD (0.44) | HSD17B10ALDH1A1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL6241038 | 0.85 | ALOX5AP (0.43) | HSD17B10ALDH1A1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL19768838 | 0.85 | PDE8B (0.42) | HSD17B10ALDH1A1ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL23142701 | 0.84 | RAB9A (0.39) | TSHRL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, ZFX, HBG1 | HSD17B10 1799/4885ALDH1A1 715/4885ALOX5AP 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.